FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379281848> ?p ?o ?g. }

• W4379281848 endingPage "e21191" @default.
• W4379281848 startingPage "e21191" @default.
• W4379281848 abstract "e21191 Background: A growing number of targeted therapy approvals for mNSCLC have dramatically increased requirements for molecular testing. Identifying and addressing real-world challenges mNSCLC care teams face due to resulting workflow shifts is essential to optimize patient outcomes. Methods: In March–September 2022, 126 health care professionals (HCPs) who treat NSCLC at 10 US community oncology clinics completed surveys assessing practice patterns, challenges, and confidence related to biomarker testing and targeted therapy use. HCPs (N = 105) participated in interdisciplinary audit and feedback (AF) sessions to examine clinical evidence and develop clinic-specific action plans to address identified gaps. Results: Participants represented the interprofessional NSCLC care team: medical oncologists (32%), pathologists (1%), radiation oncologists (1%), pulmonologists (2%), PCP/other physicians (5%), advanced practice professionals (22%), nurses (19%), and other HCPs (e.g. patient navigator, practice manager; [19%]). At the time of the program there were 9 NCCN-recommended biomarkers for mNSCLC. Less than half of HCPs reported regular testing for 4 of these biomarkers (Table 1). The majority of HCPs were somewhat (52%) or very/extremely (23%) likely to start treatment prior to receiving molecular testing results. Top reported barriers to integrating molecular diagnostics into routine practice were biopsy tissue availability/quality (45%) and determining whether to begin treatment prior to receipt of molecular testing results (43%). Gap-oriented clinic action plans aimed to improve communication between oncologists, pulmonologists, and pathologists to increase quality and efficiency of testing. A targeted therapy toolkit was developed with a panel of oncology and pathology experts and distributed to participants to address gaps in knowledge of testing practices and guidelines. HCP confidence in biomarker testing increased from 72% to 92% following the intervention. More HCPs correctly answered knowledge (43% pre-AF vs 61% post-AF) and competence (29% pre-AF vs 54% post-AF) questions following participation in the AF sessions. Conclusions: While molecular testing is critical for mNSCLC care, HCPs report sub-optimal rates of conducting testing prior to treatment and incorporating results into treatment planning. Here, we highlight an unmet need for improved interdisciplinary communication and coordination in mNSCLC care teams and an educational intervention strategy that can be used to improve HCP biomarker and targeted therapy use in mNSCLC. [Table: see text]" @default.
• W4379281848 created "2023-06-05" @default.
• W4379281848 creator A5057433128 @default.
• W4379281848 creator A5068401391 @default.
• W4379281848 creator A5081899170 @default.
• W4379281848 creator A5084379920 @default.
• W4379281848 creator A5091396661 @default.
• W4379281848 creator A5092083401 @default.
• W4379281848 date "2023-06-01" @default.
• W4379281848 modified "2023-09-25" @default.
• W4379281848 title "Examining molecular testing practices and targeted therapy use in advanced/metastatic non-small cell lung cancer (mNSCLC): A quality improvement initiative across ten community cancer centers." @default.
• W4379281848 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e21191" @default.
• W4379281848 hasPublicationYear "2023" @default.
• W4379281848 type Work @default.
• W4379281848 citedByCount "0" @default.
• W4379281848 crossrefType "journal-article" @default.
• W4379281848 hasAuthorship W4379281848A5057433128 @default.
• W4379281848 hasAuthorship W4379281848A5068401391 @default.
• W4379281848 hasAuthorship W4379281848A5081899170 @default.
• W4379281848 hasAuthorship W4379281848A5084379920 @default.
• W4379281848 hasAuthorship W4379281848A5091396661 @default.
• W4379281848 hasAuthorship W4379281848A5092083401 @default.
• W4379281848 hasConcept C126322002 @default.
• W4379281848 hasConcept C143998085 @default.
• W4379281848 hasConcept C177713679 @default.
• W4379281848 hasConcept C19527891 @default.
• W4379281848 hasConcept C2776256026 @default.
• W4379281848 hasConcept C2908861384 @default.
• W4379281848 hasConcept C512399662 @default.
• W4379281848 hasConcept C71924100 @default.
• W4379281848 hasConceptScore W4379281848C126322002 @default.
• W4379281848 hasConceptScore W4379281848C143998085 @default.
• W4379281848 hasConceptScore W4379281848C177713679 @default.
• W4379281848 hasConceptScore W4379281848C19527891 @default.
• W4379281848 hasConceptScore W4379281848C2776256026 @default.
• W4379281848 hasConceptScore W4379281848C2908861384 @default.
• W4379281848 hasConceptScore W4379281848C512399662 @default.
• W4379281848 hasConceptScore W4379281848C71924100 @default.
• W4379281848 hasIssue "16_suppl" @default.
• W4379281848 hasLocation W43792818481 @default.
• W4379281848 hasOpenAccess W4379281848 @default.
• W4379281848 hasPrimaryLocation W43792818481 @default.
• W4379281848 hasRelatedWork W102980731 @default.
• W4379281848 hasRelatedWork W1967103478 @default.
• W4379281848 hasRelatedWork W2032912323 @default.
• W4379281848 hasRelatedWork W2216151316 @default.
• W4379281848 hasRelatedWork W2372561159 @default.
• W4379281848 hasRelatedWork W2375344515 @default.
• W4379281848 hasRelatedWork W2380382254 @default.
• W4379281848 hasRelatedWork W2390152934 @default.
• W4379281848 hasRelatedWork W2610092277 @default.
• W4379281848 hasRelatedWork W3096852753 @default.
• W4379281848 hasVolume "41" @default.
• W4379281848 isParatext "false" @default.
• W4379281848 isRetracted "false" @default.
• W4379281848 workType "article" @default.